70.5  -0.25 (-0.35%)		11-13 16:00
Open: 70.74 High: 70.76 Volume: 27,874,411		Pre. Close: 70.75 Low: 70.13 Market Cap: 7,429(M)

Short term
Mid term
Targets	6-month :	97.94	1-year :	114.4
Resists	First :	83.85	Second :	97.94
Pivot price	67.13
Supports	First :	64.06	Second :	51.83
MAs	MA(5) :	70.68	MA(20) :	63.54
	MA(100) :	44.02	MA(250) :	0
MACD	MACD :	5.9	Signal :	5.9
%K %D	K(14,3) :	58.5	D(3) :	58.8
RSI	RSI(14): 62
52-week	High :	83.85	Low :	12.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MTSR ] has closed below upper band by 41.0%. Bollinger Bands are 151.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	70.66 - 71.13	71.13 - 71.56
Low:	69.31 - 69.92	69.92 - 70.48
Close:	69.57 - 70.52	70.52 - 71.38

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

Thu, 13 Nov 2025
Pfizer Completes Acquisition of Metsera - Business Wire

Mon, 10 Nov 2025
Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal - Yahoo Finance

Mon, 10 Nov 2025
Metsera falls after accepting up to $10 billion offer from Pfizer - Reuters

Sat, 08 Nov 2025
Metsera (MTSR) Hits New High on Billion-Dollar Bidding War - Yahoo Finance

Wed, 05 Nov 2025
Metsera (MTSR) Climbs to New 52-Week High as Novo Ups Acquisition Bid to $10 Billion - Yahoo Finance

Wed, 05 Nov 2025
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats - Pharmaceutical Technology

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	105 (M)
Shares Float	65 (M)
Held by Insiders	13 (%)
Held by Institutions	90.2 (%)
Shares Short	4,770 (K)
Shares Short P.Month	6,470 (K)

EPS	-3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-38.8 %
Return on Equity (ttm)	-134.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-231 (M)
Levered Free Cash Flow	-121 (M)

PE Ratio	-23.58
PEG Ratio	0
Price to Book value	21.96
Price to Sales	0
Price to Cash Flow	-32.11

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.